Aegerion Pharmaceuticals, Inc. (AEGR) 10-Q Quarterly Report November 2016

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business update for the third quarter of 2016.

Highlights


•	Aegerion recorded total net product sales of $35.4 million in the third quarter of 2016.


•	Aegerion recorded $13.4 million in net product sales of MYALEPT^® (metreleptin) for injection in the third quarter of 2016, $11.9 million, or 89% of which was from prescriptions written in the United States (U.S.). Net product sales in the third quarter include a $1.0 million sale of inventory to Shionogi for distribution in Japan, South Korea and Taiwan.


•	As of September 30, 2016, there were approximately 125 active generalized lipodystrophy (GL) patients on commercial therapy, approximately 101 of whom are U.S. patients. In the third quarter, Aegerion began adding GL patients on commercial MYALEPT via named patient sales programs in Germany, Israel and Italy.


•	Aegerion recorded $22.0 million in net product sales of JUXTAPID® (lomitapide) capsules in the third quarter of 2016, $18.6 million, or 85% of which was from prescriptions written in the U.S. As of September 30, 2016, there were approximately 393 active patients on JUXTAPID therapy globally, approximately 260 of whom are U.S. patients.


•	In September 2016, Japan’s Ministry of Health, Labor & Welfare (MHLW) granted approval for JUXTAPID in Japan for the treatment of homozygous familial hypercholesterolemia (HoFH).


•	Aegerion expects to complete its merger with QLT Inc. and to submit a marketing authorization application (MAA) for metreleptin as a potential treatment for GL and a subset of partial lipodystrophy (SPL) patients in the EU in the fourth quarter of 2016.

Chief Executive Officer Mary Szela commented, “We continue to make significant strides toward reinvigorating Aegerion and returning to growth. In the third quarter, we strengthened the commercial pillars of our business, particularly through MYALEPT. We have initiated a stronger emphasis on the education of physicians to assist in identifying appropriate GL patients eligible for metreleptin therapy. We were also encouraged to see the rate of JUXTAPID patient attrition due to PCSK9 inhibitors continue to stabilize, reinforcing our belief that there exists a core base of adult HoFH patients for whom JUXTAPID will remain a crucial therapy.”

The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Thursday, November 3, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1338042/000162828016020875/aegr-093016x10q.htm

View differences made from one quarter to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aegerion Pharmaceuticals, Inc..

Continue

Assess how Aegerion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Aegerion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Aegerion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract

Exhibit 10.2: Material Contract

Exhibit 10.3: Material Contract

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: AEGR
CIK: 1338042
Form Type: 10-Q Quarterly Report
Accession Number: 0001628280-16-020875
Submitted to the SEC: Fri Nov 04 2016 5:30:23 PM EST
Accepted by the SEC: Fri Nov 04 2016
Period: Friday, September 30, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aegr/0001628280-16-020875.htm

Aegerion Pharmaceuticals, Inc. (AEGR) SEC Filing 10-Q Quarterly report for the period ending Friday, September 30, 2016

SEC Filings

AEGR Valuations

AEGR Annual Reports

AEGR Quarterly Reports

AEGR Corporate News